Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: A qualitative patient experience cross‐sectional study-Reference-Cited by-同舟云学术

Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: A qualitative patient experience cross‐sectional study

Published:2022-01-03 Issue:3 Volume:16 Page:462-473
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Curran Desmond¹^ORCID,Cabrera Eliazar Sabater¹^ORCID,Bracke Benjamin¹^ORCID,Raymond Kimberly²^ORCID,Foster April²^ORCID,Umanzor Cindy²^ORCID,Goulet Philibert¹^ORCID,Powers John H.³^ORCID

Affiliation:

1. Value Evidence Vaccines GSK Wavre Belgium

2. Scientific Consulting QualityMetric Johnston Rhode Island USA

3. Department of Clinical Medicine George Washington University School of Medicine & Health Sciences Washington District of Columbia USA

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12929

Reference26 articles.

1. Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized Problem

2. Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness

3. Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults

4. Seasonal Incidence of Medically Attended Respiratory Syncytial Virus Infection in a Community Cohort of Adults ≥50 Years Old

5. Respiratory syncytial virus‐ and human metapneumovirus‐associated emergency department and hospital burden in adults

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age;Clinical Infectious Diseases;2024-08-05

2. Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination;The Journal of Infectious Diseases;2024-04-12

3. Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States;Infectious Diseases and Therapy;2024-03-20

4. The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years of age;Influenza and Other Respiratory Viruses;2024-02

5. Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians;Vaccines;2023-12-02